DAF ACT Commercial Solutions Opening (CSO) COVID-19 Response   2

The Department of the Air Force (DAF) has been tasked to address mission needs in response to the national crisis caused by the Corona Virus Disease 2019 (COVID-19) pandemic. The Air Force Senior Acquisition Executive (SAE) established the Department of the Air Force Acquisition COVID-19 Task Force (DAF ACT) across the acquisition enterprise (i) to execute all requirements from the Office of the Under Secretary of Defense for Defense Assisted Acquisition Cell, (DA2) and (ii) to collect and consolidate funding requests needed to recover programs from COVID-19 impacts. The DAF ACT contains four primary lines of effort (LOE's): (1) Relief for external assistance requirements; (2) Resilience for Defense Industrial Base Efforts; (3) Recovery for consolidating funding requests that minimize program impacts; and (4) Rapid for solicitation and execution of large-scale rapid small business contracts across all lines of effort.

As the U.S. Government response to the COVID-19 pandemic has evolved, the DA2 mission has also evolved to include the replenishment of the Strategic National Stockpile (SNS) and expand the domestic manufacture of key medical personnel protective equipment (PPE) items, screening and diagnostics instruments and supplies, finished drugs and active pharmaceutical ingredients and the associated finishing and delivery capabilities. The Department of the Air Force Acquisition Task Force (DAF ACT) combined with the DA2, will lead rapid solicitation and execution of contracts in support of the DA2 mission.

This CSO announcement functions as the overarching umbrella solicitation from which the Team anticipates soliciting solution briefs through separate & periodically published Areas of Interest (AOI) to meet Department of Health and Human Services (HHS) COVID-19 response priorities; with an emphasis on SNS goals that achieve (i) more coverage to ensure sufficient inventory the major PPE, equipment and drugs associated with COVID-like pandemics, (ii) greater insight to forecast requirements, (iii) use various inventory management strategies and improved visibility into supply and demand, and (iv) enhance manufacturing capacity to reduce dependency on foreign sources of supply. Example description for known potential AoIs are called out in ATTACHMENT II.

The CSO is a streamlined acquisition process that seeks to reduce acquisition timelines and acquire new, innovative solutions that companies can bring forth to meet the stated AoIs detailed in each Call. All details of the process shall be governed by this CSO unless otherwise noted or expanded upon in each AoI. Complete CSO details are contained in the attached document "DAF ACT Commercial Solutions Opening (CSO) COVID-19 Response" below.

Interested parties should continue to monitor this Notice for updated information and publication of specific AoIs.

UPDATED 12 NOV 2020: CSO FA8119-21-S-C001 is updated by amendment to publish AoI 0001 - Rapid Point of Care Testing, Closing 01 Dec 2020

UPDATED 12 NOV 2020: Correction of links at AoI-0001 - Rapid Point of Care Testing document paragraphs 3.0 and 4.0

UPDATED 13 NOV 2020:

• Add: ****Note to Vendor**** There is a technical issue with the links inside the attached PDFs. The 'Click' feature may not work. Please copy the link you desire and paste it into your browser
• Administrative update to CSO description and document; posted Revision 01
• Publish AoI-0002 - Glove Industrial Base Expansion, Closing 30 Nov 2020

UPDATED 17 NOV 2020:

• Administrative update to CSO document to correct Contracting/Agreements Officer email addresses; posted Revision 02
• Extended AoI-0001 Glove Industrial Base Expansion to 4:00 PM CST, 1 Dec 2020, posted Revision

UPDATED 20 NOV 2020:

• Post Questions and Answers document dated 20 Nov 2020.

UPDATED 30 NOV 2020:

• CSO FA8119-21-S-C001 is updated by amendment to publish AoI 0001 - Rapid Point of Care Testing Rev 01, Closing 01 Dec 2020
  • Extended AoI-0001 Rapid Point of Care Testing to 4:00 PM EST, 1 Dec 2020, posted Revision

UPDATED 4 DEC 2020

• CSO FA8119-21-S-C001 is updated by amendment to publish AoI 0001 - Rapid Point of Care Testing Rev 02, Closing 07 Dec 2020
  • Extended AoI-0001 Rapid Point of Care Testing to 4:30 PM CST, 7 Dec 2020, posted Revision

UPDATED 4 DEC 2020

CSO FA8119-21-S-C001 is updated by amendment to publish AoI 0001 - Rapid Point of Care Testing Rev 03, Closing 07 Dec 2020

• Extended AoI-0001 Rapid Point of Care Testing from 4:35 PM CST to 11:59 PM CST, 7 Dec 2020, posted Revision

UPDATED 25 JAN 2021

CSO FA8119-21-S-C001 is hereby revised to extend the viability of the CSO only to 31 March 2021, and to update primary POCs.

• This revision to the CSO does not contain any new requests to vendors and thereby does not require any responses. In the event an additional AoI is let, this CSO will be revised accordingly.

UPDATED 3 FEB 2021

CSO FA8119-21-S-C001 is hereby revised to correct the secondary Point of Contact (POC) name and email address.

• Secondary POC is Tisha McLelland, tisha.mclelland.dafact@afwerx.af.mil

UPDATED 5 FEB 2021

CSO FA8119-21-S-C001 is updated by amendment to publish AoI-0003 - Supply Chain COVID-19 Diagnostic Testing, Closing 4:00 PM CST, 07 March 2021.

UPDATED 11 FEB 2021

CSO FA8119-21-S-C001 is updated by amendment to publish AoI 0003 Supply Chain COVID-19 Diagnostic Testing Rev 01

• The revision to the CSO makes clarifications to sections 2.0 and 3.1 of the AoI.

UPDATED 7 MAR 2021

CSO FA8119-21-S-C001 is updated as follows:

• Extend AoI-0003 - Supply Chain COVID-19 Diagnostic Testing to 4PM CST, 8 March 2021
• Update and replace attachment AoI 0003 - Supply Chain COVID-19 Diagnostic Testing to reflect revision 02
• Update and replace CSO document labeled "DAF ACT Commercial Solutions Offering (CSO) COVID-19 Response Rev02". This document is updated to show the correct CSO close date of 31 March 2021 and remove Ms. Helaina Germosen as a point of contact.